WIC
CBMG

Water Island Capital’s Cellular Biomedicine Group, Inc. CBMG Stock Holding History

Water Island Capital’s Portfolio CBMG Stock Details CBMG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-133,286
Closed -$2.44M – 130
2020
Q3 		$2.44M Buy
+133,286
New +$2.24M 0.21% 36

Other funds holding CBMG

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Water Island Capital's CBMG Position: Q4 2020 in Review

Water Island Capital sold out of Cellular Biomedicine Group, Inc. (CBMG) in Q4 2020, closing a stake of 133,286 shares — an estimated $2.44M sold.

Water Island Capital first reported a position in CBMG in Q3 2020 and held it in 1 quarter. The position peaked at $2.44M in Q3 2020. 67 funds tracked by Wall St. Rank hold CBMG as of Q4 2020.

  • Water Island Capital reported no remaining Cellular Biomedicine Group, Inc. position as of Q4 2020 after selling out during the quarter.
  • Water Island Capital sold 133,286 Cellular Biomedicine Group, Inc. shares in Q4 2020, an estimated $2.44M.
  • Water Island Capital first reported a position in Cellular Biomedicine Group, Inc. in Q3 2020 and held it in 1 quarter.
  • Water Island Capital's Cellular Biomedicine Group, Inc. position peaked at $2.44M in Q3 2020.
  • 67 funds tracked by Wall St. Rank held Cellular Biomedicine Group, Inc. as of Q4 2020.

Based on Water Island Capital's 13F filing for Q4 2020, filed 10 Feb 2021.